Sarepta Therapeutics

Sarepta Therapeutics

SRPT· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -82.3% in FY2025

Douglas S. Ingram is the CEO of Sarepta Therapeutics and was paid $7.8M in FY2025 (Dec), up 296%.

Pay$100 in the stock at the end of FY20 → $13
CEO pay is from each Sarepta Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives6

See all
  1. 1Douglas S. IngramFY2025
  2. 2Louise Rodino-Klapac, Ph.D.FY2025
  3. 3Ian M. EstepanFY2025
  4. 4Cristin L. RothfussFY2025
  5. 5Ryan H. WongFY2025
  6. 6Dallan MurrayFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Sarepta Therapeutics paid its 6 named executives $26.9M in total in FY2025 (Dec). CEO Douglas S. Ingram was paid $7.8M of that.

Name
Douglas S. IngramChief Executive Officer
Louise Rodino-Klapac, Ph.D.President, Research and Development and Technical Operations
Ian M. EstepanPresident, Chief Operating Officer
Cristin L. RothfussExecutive Vice President, General Counsel
Ryan H. WongExecutive Vice President, Chief Financial Officer
Dallan MurrayFormer Executive Vice President, Chief Customer Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers17

See all

The FY2025 (Dec) proxy of Sarepta Therapeutics names 17 peer companies for pay. Among Sarepta Therapeutics and these peers, CEO pay was 11th highest of 13 and total shareholder return was the lowest of 13.

11th highest of 13in Sarepta Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:

$6.1M$33.2M

13th highest of 13in Sarepta Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:

$13$321

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board6

See all
  • Claude Nicaise, M.D.Director · 10 yr on the boardIndependentCompensation, Research and Development—Paid as an executive
  • Richard J. BarryDirector · 10 yr on the boardIndependentAudit, Compensation, Nominating and Corporate Governance (Chair)—Paid as an executive
  • Douglas S. IngramDirector · 8 yr on the boardNot independent—Paid as an executive
  • Stephen L. Mayo, Ph.D.Director · 4 yr on the boardIndependentAudit, Research and Development—Paid as an executive
  • Kathryn J. Boor, Ph.D.Director · 3 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive
  • Deirdre ConnellyDirector · 1 yr on the boardIndependentCompensation (Chair), Nominating and Corporate Governance—Paid as an executive

The board of the latest proxy (FY2025).

Shared directors

Activity

  1. Pay
    Sarepta Therapeutics Division head pay rose 63% to $4.5M. The stock fell 82% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Sarepta Therapeutics COO pay rose 61% to $4.4M. The stock fell 82% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Sarepta Therapeutics CEO pay rose 296% to $7.8M. The stock fell 82% in FY2025 (Dec).
    DEF 14A
  4. Board
    Deirdre Connelly joined the board of Sarepta Therapeutics. Deirdre Connelly now sits on 4 public boards.
    3
  5. Pay
    Sarepta Therapeutics General counsel pay fell 27% to $2.6M. The stock rose 26% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Sarepta Therapeutics General counsel pay fell 27% to $3.7M. The stock rose 44% in FY2022 (Dec).
    DEF 14A
  7. Pay
    Sarepta Therapeutics Division head pay fell 26% to $2.7M. The stock rose 26% in FY2024 (Dec).
    DEF 14A
  8. Pay
    Sarepta Therapeutics Division head pay fell 54% to $3.9M. The stock rose 44% in FY2022 (Dec).
    DEF 14A
  9. Pay
    Sarepta Therapeutics COO pay fell 26% to $2.8M. The stock rose 26% in FY2024 (Dec).
    DEF 14A
  10. Pay
    Sarepta Therapeutics COO pay fell 25% to $3.8M. The stock rose 44% in FY2022 (Dec).
    DEF 14A
  11. Pay
    Sarepta Therapeutics CEO pay rose 19% to $2.0M. The stock rose 26% in FY2024 (Dec).
    DEF 14A
  12. Pay
    Sarepta Therapeutics CEO pay rose 7,980% to $124.9M. The stock rose 44% in FY2022 (Dec).
    DEF 14A
  13. Pay
    Sarepta Therapeutics Executive Vice President, Chief Technical Operations Officer pay fell 28% to $2.5M. The stock rose 26% in FY2024 (Dec).
    DEF 14A
  14. Board
    Deirdre Connelly joined the board of Sarepta Therapeutics. Deirdre Connelly sits on no other public board.
    3
  15. Pay
    Sarepta Therapeutics CEO pay fell 99% to $1.7M. The stock fell 26% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 24, 2026FY2025
Annual report10-KMar 2, 2026FY2025
Proxy statementDEF 14AApr 24, 2025FY2024
Annual report10-KFeb 28, 2025FY2024
Proxy statementDEF 14AApr 24, 2024FY2023
Annual report10-KFeb 28, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data